6 times per 24 hours (1200 ,g/24 h); the remaining 13 boys insufflated 500 ,tg 12-hourly (1000 ,ug/24 h).
An LH-RH test (50 , ug IV) was carried out before and after therapy. Full descent of the testis into the scrotum was obtained in 7 out of the 22 cases; in a further 6 cases the testis moved down the inguinal canal.
Basal values of luteinising hormone and follicle-stimulating hormone and those for pituitary reserve remained unchanged before and after therapy, and were similar to the values of a control group. No correlation was found between response to therapy and bone age, testosterone level in serum, basal values or pituitary reserve of luteinising hormone or follicle-stimulating hormone.
Luteinising hormone-releasing hormone (LH-RH) therapy in the adult male affected by secondary hypogonadism is known to be effective (Isidori et al., 1974; Mortimer et al., 1974a, b) . This releasing hormone, given by nasal spray, was also successfully used in the treatment of adult hypogonadotrophic hypogonadism (Isidori et al., 1974) and cryptorchidism in prepubertal boys (Happ et al., 1975) . Since cryptorchidism is sometimes associated with gonadotrophin deficiency (Job et a!., 1974; Koch and Rahlf, 1975; Hadziselimovic et al., 1976) , we have studied the therapeutic effectiveness of LH-RH in relation to the pituitary reserve of gonadotrophins.
Materials and methods
Twenty-two boys with unilateral undescended testicle, aged from 5 to 11 years, were treated. Bone age ranged from 4 years 10 months to 11 years 4 months and the difference between chronological and bone age never exceeded 6 months. All fell into the prepubertal stage of sexual development, the first stage of Tanner's (1962) classification. None had received previous medical or surgical treatment for testicular maldescent. In all cases the undescended testes were located in the inguinal canal, apparently along the normal descent way; none had retractile testes. Received 5 August 1977 With permission from the parents, an LH-RH test (50 jig IV) was performed (Cacciari et al., 1976 ) and treatment with LH-RH nasal spray (Hoechst AG) begun on the next day according to the following schedule. Therapy was given to 9 boys (group A) (mean bone age 7 years 4 months) who insufflated, according to the method of Happ etal., 100 jig to each nostril at 7, 8, 12 am, and 1, 7, 8 pm, a daily intake of 1200 V*g LH-RH. 13 boys (group B) (mean bone age 7 years 8 months) received 500 jig of the releasing hormone at 8 am (200 jig into the right nostril and 300 t±g into the left nostril) and at 8 pm (300 ,ug into the right nostril and 200 ,ug into the left nostril, a daily intake of 1000 Vg). LH-RH was given for 7 days, and the day after completing therapy an LH-RH test was repeated.
The pituitary reserve of gonadotrophins was studied by evaluating the peak, the maximum increase, and the area of the curve (Cacciari et al., 1975 (Cacciari et al., 1974) . Serum gonadotrophins were measured by the double antibody radioimmunoassay method of Reuter et al. (1973) .
For statistical analysis Student's t test was used. In order to study correlations between bone age, basal testosterone, pituitary reserve, and response to therapy, the patients were classified as follows: (1) no response (the position of the testis did not alter); (2) partial response (definite movement down the inguinal canal); and (3) full descent of the testis into the scrotum.
Results from LH-RH tests carried out on 29 short normal boys served as controls.
Results
Treatment of the 22 cases resulted in 7 (32 %) achieving descent of the testis into the scrotum. Of these, 2 (22 %) were on dosage scheme A, and 5 (39%) on scheme B. In 6 cases (27 %), 3 from each dosage group, the effect on the testicular position was partial. In the remaining 9 cases (41 %) there was no effect on the testicular position. No difference in the clinical response of the two dosage schemes was observed.
The basal values for luteinising hormone (LH) and follicle-stimulating hormone (FSH) and the pituitary LH and FSH reserve in the 22 cases did not alter after therapy (Table) (Bader, 1971) . So great a variability cannot be due only to the differences in treatment, but must imply that different criteria are used in evaluating cryptorchidism and in differentiating true cryptorchidism from retractile or ectopic testis. We think that we can exclude those cases where the testes were retractile, since the testis could not be brought down into the scrotum despite repeated examinations. On the other hand, we cannot be certain that there was no case of ectopic testis as it is well known how difficult it is to differentiate this.
Our results suggest that the hormone need be administered in only two injections per 24 hours, and that the effectiveness of therapy is independent of age. We found no correlation between response to therapy and bone age or basal testosterone level.
The rationale for treating cryptorchidism with LH-RH nasal spray was the efficacy of such treatment for secondary hypogonadism in the adult (Isidori et al., 1974) , and the finding of an LH deficit in a certain number of cryptorchid patients (Koch and Rahlf, 1975; Hadziselimovic et al., 1976; Werder et al., 1976 We thank Dr M. Sesso, Farbewerke Hoechst AG, for supplies of synthetic LH-RH, and Alfa Farmaceutici for co-operation in producing antisera.
